Ibrutinib

Spécifications

936563-96-1Numéro CAS

805-642-2Numéro CE

1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-oneNom IUPAC

C25H24N6O2Formule chimique

440.5 g/molMasse molaire

Ibrutinib; 936563-96-1; PCI-32765; IMBRUVICA; PCI 32765; CRA-032765; PCI32765; ibrutinibum; Pc-32765; 1X70OSD4VX; PCI-32765-00; CHEBI:76612; DTXSID60893450; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; RefChem:57737; BTK Inhibitor PCI-32765; L01XE27; DTXCID601323465; 805-642-2; Ibrutinib (PCI-32765); (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; MFCD20261150; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; PCI-32765 (Ibrutinib); C25H24N6O2; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one; Ibrutinib [USAN]; Ibrutinib [USAN:INN]; UNII-1X70OSD4VX; JNJ 02; Imbruvica (TN); 1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one; Ibrutinib (Standard); CRA 032765; Ibrutinib, Free Base; IBRUTINIB [INN]; IBRUTINIB [JAN]; IBRUTINIB [MI]; Ibrutinib (JAN/USAN); Ibrutinib Intermediate 2; IBRUTINIB [VANDF]; IBRUTINIB [WHO-DD]; Imbruvica; PCI-32765; MLS006010041; SCHEMBL201859; Ibrutinib - Bio-X trade mark; GTPL6912; orb1307353; orb3141322; PCI-32765 (Ibrutinib)?; IBRUTINIB [ORANGE BOOK]; CHEMBL1873475; BDBM98652; HSDB 8260; EX-A066; XYFPWWZEPKGCCK-GOSISDBHSA-N; GLXC-90098; BDBM50357312; EBC-11432; HY-10997R; NSC800769; AKOS022185476; DB09053; EX-5960; FA34130; NSC-800769; NCGC00187912-01; NCGC00187912-02; NCGC00187912-03; NCGC00187912-12; NCGC00187912-16; NCGC00187912-17; NCGC00187912-18; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidyl]prop-2-en-1-one; AC-26942; BI164531; BP-43643; HY-10997; SMR004701213; NS00072153; SW218096-2; EN300-97039; D10223; F799864; A1-01649; Q5984881; BRD-K70301465-001-02-6; BRD-K70301465-001-05-9; Z1302446275; (R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 936563-96-1, Pci-32765, Imbruvica, Pci 32765, Ibrutinib (pci-32765), Pci-32765 (ibrutinib); Ibrutinib MicronizedSynonymes